Explore comprehensive insights into antibodies, their functions, and latest research. Stay informed with expert analysis and updates in the field of immunology.
April 2026 activity saw consolidation in the ADC space, continued expansion of next-generation antibody formats (including DACs and trispecifics), and strong financing for platform-driven oncology innovation. Strategic M&A and high-value partnerships highlighted sustained interest in complex biologics and targeted delivery technologies.
March 2026 saw a surge in antibody dealmaking, focusing on T-cell engagers and autoimmune applications, alongside advancements in targeted protein degradation.
You can also contact us on the Scientist and Science Exchange marketplaces.
Our website uses cookies to improve your experience. Read our Privacy Policy to find out more.
Biointron uses cookies and similar technologies to ensure proper website functionality, understand how visitors use our website, and improve our content and services. Necessary cookies are enabled by default.
By clicking “Accept All”, you agree to the use of all cookies, including analytics and optional cookies that help us understand website usage and improve user experience. By clicking “Reject Non-Essential”, only necessary cookies will be used.
You may manage or change your cookie preferences at any time by clicking “Cookie Settings” at the bottom of the website.
For more information about how we use cookies and process personal data, please review our Privacy Policy.
